Short Interest

Showing 2349 articles
Business

C4 Therapeutics: Can Its Protein-Degrading Tech Ignite a Biotech Rally?

Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.

Business

REV Group Merges Into Terex, Shifting Investor Landscape and Strategic Focus

The completion of REV Group's merger with Terex Corporation marks a significant corporate realignment, moving the specialty vehicle manufacturer from a standalone NYSE listing to a subsidiary within a larger industrial equipment platform. This restructuring alters how investors track performance and assess exposure to key markets like emergency services and recreational vehicles.

Business

Palantir Shatters Records as U.S. AI Demand Fuels Historic Growth

Palantir Technologies' fourth-quarter earnings reveal a seismic shift, with U.S. commercial revenue for its AI Platform soaring 137%. The data analytics firm posted its highest growth rate as a public company, powered by massive government contracts and enterprise adoption, while setting aggressive targets for the year ahead.

Business

Brunswick's Strong Q4 and Aggressive Buybacks Fuel Investor Debate on Valuation

Brunswick Corporation (NYSE:BC) delivered robust fourth-quarter results, driven by strength across all segments, particularly its propulsion business. While management expressed optimism for 2026, the company's accelerated share repurchases have sparked a fresh debate among analysts regarding its valuation and the sustainability of its current momentum.